12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATI-5923: Phase II data

In an open-label Phase II trial, ATI-5923 produced stable control of anticoagulation for a mean TTR of 72%. Stable control was achieved for a mean TTR of 59% in...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >